الانتقال إلى المحتوى الرئيسي
xMedica

NCT07353931ClinicalTrials.gov

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Osteoarthritis Knee Pain, and Obesity or Overweight (ENLIGHTEN-4)

قيد التجنيديقبل مشاركين الآن، وفقاً لسجل السجل.
التواصل مع هذه الدراسة

باختصار

The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in…

المرحلة 3مطلوب 900 مشارك152 موقعاً14 دولة

الفئات

مسجَّلة في سجل واحد

يمكن أن تُسجَّل دراسة واحدة في عدة سجلات. نعرضها مرة واحدة ونربط بكل سجل نحتفظ به.

تُعرض معلومات التجربة كما نشرها السجل، بلغتها الأصلية.

هل أنت مهتم بهذه الدراسة؟

تسجيل الدخول أو أنشئ حسابًا لتسجيل اهتمامك ومتابعة هذه الدراسة.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-01-21; recorded start 2026-02-09
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 347 other studies in this databaseCounted from the lead sponsor named in the record (Eli Lilly and Company)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 2 conditions.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding13/20

    Double-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 161 sites

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study, international in scope: 900 participants (target), run at 152 sites, across 14 countries.

How this score is built
  • Enrolment29/40

    900 participants (target)

  • Site count24/25

    161 sites

  • Country count12/15

    15 countries

  • Planned duration7/10

    Planned over about 27 months

  • Sponsor scale9/10

    Eli Lilly and Company has led 326 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

ملخص

The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening.

الحالات

  • Osteoarthritis
  • Overweight or Obesity

الأهلية

الأهلية
الجنسالجميع
الأعمار18 Yearsلا حد أقصى
المتطوعون الأصحّاءلا

الأهلية كما كُتبت في السجل

Inclusion Criteria: * Have a body mass index (BMI) of 27 kilograms per square meter (kg/m²) or higher at screening * Have a stable body weight (less than 5% body weight change) for 90 days prior to screening * Have tried at least once to lose weight through diet but were unsuccessful * Have osteoarthritis of the knee and at least one of the following conditions: * Be over 50 years old * Have morning knee stiffness that lasts about 30 minutes * Have a crackling or grinding sound or feeling in the knee Exclusion Criteria: * Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed greater than 1 year before screening) * Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening) * Have type 1 diabetes, type 2 diabetes, or any other type of diabetes * Have an active knee infection * Have had within 90 days prior to screening: * heart attack * stroke * coronary artery revascularization * unstable angina, or * hospitalization due to congestive heart failure * Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure * Have taken medications or alternative remedies intended for weight loss within 90 days of screening

الأهلية في عبارات بسيطة

لم تُقسَّم معايير هذا السجل إلى عبارات منفصلة بعد. نص السجل أعلاه كامل وهو النسخة المُعتمَدة.

تصميم الدراسة

تصميم الدراسة
نوع الدراسةتدخّلية
المرحلةالمرحلة 3
التخصيصمعشّاة
نموذج التدخّلPARALLEL
الغرض الأساسيTREATMENT
التعميةDOUBLE (2)
التجنيدمطلوب 900 مشارك

الجهة الراعية والمتعاونون

  • Eli Lilly and Company الجهة الراعية

الأذرع والتدخلات

  • Eloralintide (YOA1)EXPERIMENTAL

    Participants will receive eloralintide subcutaneously (SC)

  • Placebo (YOA1)PLACEBO_COMPARATOR

    Participants will receive placebo SC

  • Eloralintide (YOA2)EXPERIMENTAL

    Participants will receive eloralintide SC

  • Placebo (YOA2)PLACEBO_COMPARATOR

    Participants will receive placebo SC

التدخلات

  • دواء Eloralintide

    Administered SC

  • دواء Placebo

    Placebo administered SC

مقاييس النتائج

  1. مقياس النتيجة الأولي

    Percent Change from Baseline in Body Weight

    Percent Change from Baseline in Body Weight

    الإطار الزمني Baseline, Week 64

  2. مقياس النتيجة الأولي

    Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score

    Change from Baseline in the WOMAC Pain Subscale Score

    الإطار الزمني Baseline, Week 64

  3. مقياس النتيجة الثانوي

    Change from Baseline in Systolic Blood Pressure (SBP)

    Change from Baseline in SBP

    الإطار الزمني Baseline, Week 64

  4. مقياس النتيجة الثانوي

    Percent Change from Baseline in Triglycerides

    Percent Change in Baseline in Triglycerides

    الإطار الزمني Baseline, Week 64

  5. مقياس النتيجة الثانوي

    Change from Baseline in Short Form-36 (SF-36 v2) Acute Form Physical Functioning Domain Score

    Change from Baseline in SF-36 v2 Score

    الإطار الزمني Baseline, Week 64

  6. مقياس النتيجة الثانوي

    Percent Change from Baseline in High Sensitivity, C-reactive Protein (hsCRP)

    Percent Change from Baseline in hsCRP

    الإطار الزمني Baseline, Week 64

  7. مقياس النتيجة الثانوي

    Change from Baseline in the WOMAC Physical Function Subscale Score

    Change from Baseline in the WOMAC Physical Function Subscale Score

    الإطار الزمني Baseline, Week 40, Week 64

  8. مقياس النتيجة الثانوي

    Change from Baseline WOMAC Pain Subscale Score

    Change from Baseline WOMAC Pain Subscale Score

    الإطار الزمني Baseline, Week 40

  9. مقياس النتيجة الثانوي

    Change from Baseline in Distance Walked During the 6-Minute Walk Test

    Change from Baseline in Distance Walked During the 6-Minute Walk Test

    الإطار الزمني Baseline, Week 64

  10. مقياس النتيجة الثانوي

    Change from Baseline in Body Mass Index (BMI)

    Change from Baseline in BMI

    الإطار الزمني Baseline, Week 64

  11. مقياس النتيجة الثانوي

    Change in Medication Use

    Change in Medication Use

    الإطار الزمني Baseline, Week 64

  12. مقياس النتيجة الثانوي

    Change from Baseline in SF-36v2 Acute Form Domain Scores With Exception of the Physical Functioning Domain Score

    Change from Baseline in SF-36v2 Acute Form Domain Scores With Exception of the Physical Functioning Domain Score

    الإطار الزمني Baseline, Week 64

  13. مقياس النتيجة الثانوي

    Change from Baseline in Health Status EQ-5D-5L Health State Utility

    Change from Baseline in Health Status EQ-5D-5L Health State Utility

    الإطار الزمني Baseline, Week 64

  14. مقياس النتيجة الثانوي

    Percent Change from Baseline in Fasting Insulin

    Percent Change from Baseline in Fasting Insulin

    الإطار الزمني Baseline, Week 64

  15. مقياس النتيجة الثانوي

    Percent Change from Baseline in Total Cholesterol

    Percent Change from Baseline in Total Cholesterol

    الإطار الزمني Baseline, Week 64

  16. مقياس النتيجة الثانوي

    Change from Baseline in Waist Circumference

    Change from Baseline in Waist Circumference

    الإطار الزمني Baseline, Week 64

  17. مقياس النتيجة الثانوي

    Percent Change from Baseline in Hemoglobin A1c (HbA1c)

    Percent Change from Baseline in HbA1c

    الإطار الزمني Baseline, Week 64

  18. مقياس النتيجة الثانوي

    Change from Baseline in WOMAC Stiffness Subscale Score

    Change from Baseline in WOMAC Stiffness Subscale Score

    الإطار الزمني Baseline, Week 64

  19. مقياس النتيجة الثانوي

    Change from Baseline in WOMAC Total Score

    Change from Baseline in WOMAC Total Score

    الإطار الزمني Baseline, Week 64

  20. مقياس النتيجة الثانوي

    Achievement of Improved Categorical Shift in Patient Global Impression of Severity (PGIS) - Target Knee Pain

    Achievement of Improved Categorical Shift in PGIS - Target Knee Pain

    الإطار الزمني Baseline, Week 64

  21. مقياس النتيجة الثانوي

    Achievement of Improved Categorical Shift in Patient Global Impression of Severity (PGIS) - Target Knee Function

    Achievement of Improved Categorical Shift in PGIS - Target Knee Function

    الإطار الزمني Baseline, Week 64

  22. مقياس النتيجة الثانوي

    Change from Baseline in Average Pain Intensity Numeric Rating Scale (API-NRS) Score

    Change from Baseline in API-NRS Score

    الإطار الزمني Baseline, Week 64

  23. مقياس النتيجة الثانوي

    Change from Baseline in Worst Pain Intensity Numeric Rating Scale (WPI-NRS) Score

    Change from Baseline in WPI-NRS Score

    الإطار الزمني Baseline, Week 64

  24. مقياس النتيجة الثانوي

    Pharmacokinetics (PK): Maximum Concentration at Steady State (Cmax, ss)

    PK: Cmax, ss

    الإطار الزمني Baseline through Week 64

  25. مقياس النتيجة الثانوي

    PK: Area Under the Concentration Versus Time Curve for One Dosing Interval at Steady State (AUC(0-T)ss)

    PK: AUC(0-T)ss

    الإطار الزمني Baseline through Week 64

  26. مقياس النتيجة الثانوي

    Number of Participants with Allowed Concomitant Pain Medication

    Number of Participants with Allowed Concomitant Pain Medication

    الإطار الزمني Baseline, Week 64

التواريخ

التواريخ
تاريخ البدء9 فبراير 2026 (فعلي)
الإتمام الأولي1 مارس 2028 (تقديري)
الإتمام1 مايو 2028 (تقديري)
أول نشر21 يناير 2026 (فعلي)
آخر تحديث8 سبتمبر 2026
النتائج منشورةغير مذكور في سجل السجل
آخر تأكيد للحالةسبتمبر 2026

فعلي يعني أن الحدث وقع. تقديري يعني أن الجهة الراعية تتوقعه. للكلمتين معنيان مختلفان.

المواقع

126 موقعاً قيد التجنيد

Argentina

Argentina
المنشأةالمدينةالولاية أو المنطقةالحالة
Centro Privado de Medicina Familiar / Mindout ResearchBuenos Airesلم يبدأ التجنيد بعد
Centro Médico ArsemaBuenos Airesلم يبدأ التجنيد بعد
Stat Research S.A.Buenos Airesلم يبدأ التجنيد بعد
Organizacion Medica de InvestigacionBuenos Airesلم يبدأ التجنيد بعد
CARDIAMET Investigaciones MédicasBuenos Airesلم يبدأ التجنيد بعد
Centro de Investigaciones Clínicas BaigorriaGranadero Baigorriaلم يبدأ التجنيد بعد
INECO Neurociencias OroñoRosarioلم يبدأ التجنيد بعد
Instituto Especialidades de la Salud RosarioRosarioلم يبدأ التجنيد بعد
Centro de Investigaciones Médicas TucumanSAN M. de Tucumanلم يبدأ التجنيد بعد
Medicina ReumatológicaSan Fernandoلم يبدأ التجنيد بعد
Instituto de Alta Complejidad San IsidroSan Isidroلم يبدأ التجنيد بعد
Centro Polivalente de Asistencia e Investigacion Clinica - CER San JuanSan Juanلم يبدأ التجنيد بعد
Centro de Investigaciones ReumatológicasSan Miguel de Tucumánلم يبدأ التجنيد بعد
Go Centro Medico San NicolásSan Nicolásلم يبدأ التجنيد بعد

Belgium

Belgium
المنشأةالمدينةالولاية أو المنطقةالحالة
Antwerp University HospitalEdegemقيد التجنيد
Reuma Clinic, Locatie JaarbeurslaanGenkقيد التجنيد
UZ GentGhentقيد التجنيد
KormontKluisbergenقيد التجنيد
UZ LeuvenLeuvenقيد التجنيد
MeclinasMechelenقيد التجنيد
ZNA Jan PalfijnMerksemلم يبدأ التجنيد بعد
Medisch Centrum Latem (Hip Clinic) - Algemeen Ziekenhuis Maria Middelares LocationSint-Martens-Latemلم يبدأ التجنيد بعد

Brazil

Brazil
المنشأةالمدينةالولاية أو المنطقةالحالة
Centro de Pesquisa Sao LucasCampinasمُعلَّق
IBPClin - Instituto Brasil de Pesquisa ClínicaRio de Janeiroمُعلَّق
CPHosp Medicina, Ensino e Pesquisa (CPQuali)São Pauloمُعلَّق
INTEGRA - Pesquisa Clínica e InfusõesSão Pauloمُعلَّق
CEPIC - Centro Paulista de Investigação ClínicaSão Pauloمُعلَّق
Hospital das Clinicas FMUSPSão Pauloمُعلَّق

Canada

Canada
المنشأةالمدينةالولاية أو المنطقةالحالة
Apex TrialsGuelphقيد التجنيد
G.R.M.O. (Groupe de recherche en maladies osseuses) Inc.Québecلم يبدأ التجنيد بعد
Diex Recherche Inc. Division QuebecQuébecقيد التجنيد
Stouffville Medical Research Institute Inc.Stouffvilleقيد التجنيد
Maple Leaf ResearchTorontoقيد التجنيد
Dr. Anil K. Gupta Medicine Professional CorporationTorontoقيد التجنيد
Diex Recherche Inc. Division VictoriavilleVictoriavilleقيد التجنيد

China

China
المنشأةالمدينةالولاية أو المنطقةالحالة
Beijing Ji Shui Tan HospitalBeijingقيد التجنيد
The First Afflilated Hospital of Bengbu Medical CollegeBengbuقيد التجنيد
Jilin Province People's HospitalChangchunقيد التجنيد
The Second Hospital of Jilin UniversityChangchunلم يبدأ التجنيد بعد
Xiangya Hospital Central South UniversityChangshaقيد التجنيد
2nd Affiliated Hospital Chongqing Medical UniversiChongqingقيد التجنيد
The Second Affiliated hospital of Zhejiang University school of medicineHangzhouقيد التجنيد
The Second People's Hospital of HefeiHefeiقيد التجنيد
Jinan Central HospitalJinanقيد التجنيد
The First Affiliated Hospital of Henan University of Science &TechnologyLuoyangقيد التجنيد
Nanjing First HospitalNanjingقيد التجنيد
Zhongda Hospital Southeast UniversityNanjingقيد التجنيد
The Second Affiliated Hospital of Nanjing Medical UniversityNanjingقيد التجنيد
Jiangsu Province HospitalNanjingقيد التجنيد
The first affiliated hospital of Ningbo universityNingboقيد التجنيد

يُدرَج 102 موقع إضافي في سجل السجل.

مستندات الدراسة

لا تُرتبط أي مستندات في سجل السجل هذا.

التغيّرات عبر الزمن

  1. 6 أغسطس 2026

    أُزيل موقع

    9 sites removed (152 total)

    161152